Scientists test safety of longer cancer drug dosing in small group
NCT ID NCT02860676
Summary
This study aimed to check the safety of giving the experimental drug cirmtuzumab for 6 to 12 months. It involved only 3 people with chronic lymphocytic leukemia (CLL) who had safely taken the drug in a previous trial. The main goal was to see if this longer treatment schedule was safe and tolerable, not to test if it cured the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.